Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T21:11:41.599Z.
Calculation as of: 2026-10-06T21:11:41.599Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: df0d51bc4c7c4fe031789de0e9442acf829cec50a05ec95901a80cda74a8a9f3
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$3.06B
EV/EBIT Ratio
N/A
TTM Avg
142.94x
3Y Avg
142.94x
5Y Avg
142.94x
Market Cap
$2.99B
EV/EBIT Ratio
89.69x
TTM Avg
650.30x
3Y Avg
650.30x
5Y Avg
650.30x
Market Cap
$3.12B
EV/EBIT Ratio
N/A
TTM Avg
9.47x
3Y Avg
9.47x
5Y Avg
9.47x
Market Cap
$2.77B
EV/EBIT Ratio
38.84x
TTM Avg
46.98x
3Y Avg
64.49x
5Y Avg
64.49x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | $3.03B | N/A | N/A | N/A | N/A |
| Denali Therapeutics Inc. (DNLI)vs › | $3.06B | N/A | 142.94x | 142.94x | 142.94x |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $2.99B | 89.69x | 650.30x | 650.30x | 650.30x |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.12B | N/A | 9.47x | 9.47x | 9.47x |
| Dyne Therapeutics, Inc. (DYN)vs › | $2.88B | N/A | N/A | N/A | N/A |
| Tarsus Pharmaceuticals, Inc. (TARS)vs › | $3.19B | N/A | N/A | N/A | N/A |
| TransMedics Group, Inc. (TMDX)vs › | $2.77B | 38.84x | 46.98x | 64.49x | 64.49x |
| CareDx, Inc (CDNA)vs › | $3.30B | N/A | 18.58x | 18.58x | 18.58x |
| Viking Therapeutics, Inc. (VKTX)vs › | $3.31B | N/A | N/A | N/A | N/A |
| AtriCure, Inc. (ATRC)vs › | $2.73B | 189.62x | 169.00x | 169.00x | 169.00x |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
